Which muscles hold their strength through weight loss? A gene hunt

One of the persistent worries about intentional weight loss — sharpened lately by the scale of loss achievable with GLP-1 drugs — is that the body sheds muscle along with fat, and with it strength and function. A secondary analysis of the CALERIE trial, published in Obesity on 1 September, does not resolve that worry, but it points at where the biology of an answer might live [s1].

The parent trial

CALERIE was a two-year randomised controlled trial comparing sustained caloric restriction against ad libitum eating in healthy adults who did not have obesity, designed originally to test whether eating less slows markers of ageing [s2]. That design detail matters here: these were not patients losing large amounts of weight for metabolic disease, but lean-to-normal-weight volunteers cutting calories, which makes any loss of lean tissue a cleaner signal and a harder test [s1].

What the sub-study looked at

The authors examined changes in whole-body mass and in knee-extensor strength over the first 12 months of the trial, and then, in a subset of participants who had provided skeletal-muscle biopsies, profiled which genes' expression tracked with strength change [s1]. Crucially, they modelled the relationship between strength change and gene expression while controlling for whole-body mass change — an attempt to isolate the molecular signature of holding on to strength from the simple fact of losing weight [s1].

The finding

In the transcriptomic subset of 42 individuals, 151 genes were significantly associated with change in strength after accounting for change in whole-body mass [s1]. Among them were HSP90AA1 and EIF3A [s1]. Pathway analyses implicated processes related to cellular proliferation, immune regulation and protein secretion [s1].

That is the whole of the positive result, and it should be read as a hypothesis-generating map, not a set of drug targets. Forty-two people is a small sample for transcriptomics, the analysis is a secondary one the trial was not designed to run, and an association between a gene's expression and a change in strength does not establish that the gene causes strength to be preserved [s1]. Named genes like HSP90AA1 are plausible characters — it is a chaperone involved in protein folding and stress responses — but plausibility is not proof of a mechanism here.

Why it is interesting anyway

The value is in the framing. Most discussion of muscle loss during weight loss treats it as a quantity problem — how many kilograms of lean mass, offset by how much resistance exercise or protein. This analysis reframes it as partly a quality and regulation problem: given the same amount of mass lost, some people's muscle keeps its strength better than others', and that gap has a molecular correlate [s1]. If that holds up, it opens the possibility of identifying who is most vulnerable to functional decline during weight loss, rather than treating everyone identically.

The specific endpoint the authors chose — knee-extensor strength — is a sensible one, because lower-limb strength is closely tied to the everyday functions that matter as people age: standing from a chair, climbing stairs, avoiding falls [s1]. Weight loss that quietly erodes that capacity trades a cardiometabolic gain for a functional loss, which is precisely the concern the original CALERIE investigators built the trial to monitor over two years [s2]. That the strongest genetic signals sat in pathways for cellular proliferation, immune regulation and protein secretion, rather than the obvious contractile-protein genes, is itself a hint that strength preservation may run through tissue maintenance and repair as much as through muscle bulk [s1]. Whether any of these pathways can actually be nudged — by training, by nutrition, or by drugs — is the question the analysis raises and cannot answer.

Limits and what to watch

The population is the study's biggest caveat for anyone thinking about obesity care: CALERIE enrolled adults without obesity, losing weight by diet alone, so the findings do not transfer directly to people losing much larger amounts on incretin drugs [s1][s2]. Whether the same genes matter under rapid pharmacological weight loss, and whether any of them can be moved by exercise, protein or drugs to protect strength, are entirely open questions this single sub-study cannot touch. It is a lead, and it is honest about being one.

This article is informational and does not constitute medical advice.